Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  eribulin mesylate
Find trials that include:  Any drugs shown
Results 1-19 of 19 for your search:
Start Over
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: E7389-A001-303, NCI-2014-01285, NCI-2014-00255, RU011201I, NCT02037529
Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PHII-75, NCI-2009-00170, CDR0000492014, 7435, CCC-PHII-75, NCI-7435, NCT00365157
Eribulin Mesylate and Cyclophosphamide in Treating Patients With Solid Tumor Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: 11996, NCI-2012-00436, NCT01554371
Multitargeted Tyrosine Kinase Inhibitor PLX3397 and Eribulin Mesylate in Treating Patients with Triple-Negative Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12751, NCI-2015-01321, 141658, CC#12751, NCT01596751
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 7674, NCI-2012-00892, NCT01613768
Eribulin Mesylate in Treating Patients with Advanced or Recurrent Cervical Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 5C-11-2, NCI-2012-01378, HS-11-00547, NCT01676818
Eribulin Mesylate in Treating Patients with HER2-Negative Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-077, NCI-2013-01115, NCT01827787
Eribulin Mesylate in Treating Patients with Previously Treated Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8093, NCI-2013-01326, NCT01908101
Eribulin Mesylate, Trastuzumab, and Pertuzumab in Treating Patients with HER2-Positive Breast Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-163, NCI-2013-01826, 688097, 707389, NCT01912963
Trastuzumab and Pertuzumab Alone or in Combination With Hormone Therapy or Eribulin Mesylate in Treating Older Patients With Stage IIIB-IV HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: GCC1303, NCI-2014-00874, 1303GCC, ML28192, NCT02000596
Eribulin Mesylate in Treating Patients with Recurrent or Refractory Osteosarcoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 16 to 49
Trial IDs: AOST1322, NCI-2014-00621, COG-AOST1322, NCT02097238
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients with Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: PHII-130, NCI-2014-01294, P9653_A02PAMDREVW01, 9653, NCT02178241
Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 to 55
Trial IDs: POL-7, NCI-2014-01233, NCT01837095
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: C1073-500, NCI-2015-00521, NCT02014337
Eribulin Mesylate and Everolimus in Treating Patients with Triple-Negative Metastatic Breast Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14036, NCI-2014-00844, 112905, 117995, 119537, NCT02120469
Eribulin Mesylate in Treating Younger Patients with Refractory or Recurrent Solid Tumors or Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 months to 17 years
Trial IDs: ADVL1314, NCI-2014-00714, NCT02171260
Selinexor with Multiple Standard Chemotherapy Regimens in Treating Patients with Advanced Malignancies
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0640, NCI-2015-00693, NCT02419495
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients with Brain Metastases from Breast, Bladder, or Non-small Cell Lung Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14312, NCI-2014-02391, 113114, 120431, NCT02338037
Start Over